NAII (34) MTEX (33) AKAN (54) BTMD (62) ⌘ Pro Terminal →

Bon Natural Life Limited (Class A) (BON) — RQD Stock Rating Cockpit

$1.13 -0.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.13

Bon Natural Life Limited (Class A) (BON) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $9.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.13 (-0.19%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-6.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BON)Realized 20D OHLCV Swing Band: ±9.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY BON SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (36% of score)

SEC XBRL FY 2025 (10-K): 0.7% FCF Margin ($134.3K FCF) & 20.8% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (18% of score)

20D Institutional Volume Accumulation (±9.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.16-1.7% Next Q

Q2 (-2Q)

Grade C-$1.14+0.9% Next Q

Q3 (-1Q)

Grade D$1.15-1.7% Next Q

Current

Grade D$1.13-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BON Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BON currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Strong cash generator (21% profit margin)—profits are backed by real money, not accounting tricks.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($1.19) forces dealer call-delta covering toward $2.16.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BON• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BON Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

4830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE16% OF RANGE

L: $1$1.13H: $2

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (21% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on BON

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (80)

14.0% ROIC with 20.8% gross margin and 1.46% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (35)

13/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like BON

✓Strong cash generator (21% profit margin)—profits are backed by real money, not accounting tricks.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BON)

✓Walkthrough of BON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.72%📐 HORIZONTAL RANGE

2026-10-30O $1.15H $1.15L $1.10C $1.13VOL 23.2K

RES: $1.27SUP: $0.90SMA50: $1.15SMA200: $1.30

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BON Butterfly Map → + Track BON →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -21.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BON)

Health Care Rank #490 of 1016 ⚔️ NAII vs BON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BON vs. NAII, MTEX, AKAN, BTMD)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bon Natural Life Limited (Class A) (BON) ranks #490 by composite RQD confidence (45/100, grade D) and #901 by equity capitalization ($9.2M). Within this direct 5-issuer industry benchmark cohort, BON leads on earnings valuation at N/A trailing P/E, while BTMD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with BON at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BON ACTIVE Bon Natural Life Limited (Class A)	D	45/100	—	20.8%	—	-0.01%	$9.2M	Benchmark Subject
NAII Natural Alternatives International Inc.	E	34/100	—	7.2%	-10.8%	-4.31%	$6.9M	/naii-vs-bon →
MTEX Mannatech Incorporated	E	33/100	—	74.9%	-35.0%	-2.23%	$16.1M	/mtex-vs-bon →
AKAN Akanda Corp.	D+	54/100	—	—	—	+2.80%	$2.6M	/akan-vs-bon →
BTMD Biote Corp. (Class A)	C	62/100	—	—	85.0%	+1.74%	$42.0M	/btmd-vs-bon →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001816815

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Bon Natural Life Limited (Class A) (BON) reported GAAP revenue of $18.7M (-21.7% vs. FY2024 revenue of $23.8M , and -36.8% cumulative change since FY2023) , GAAP net income of -$2.0M, operating cash flow of $141.1K, and free cash flow of $134.3K (+101.7% YoY). On the balance sheet, BON closed FY2025 with $85.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$18.7M	-$2.0M	$141.1K	$134.3K	$85.2M	—
FY2024 (FY)	2024-09-30	$23.8M	$398.2K	-$7.7M	-$7.7M	—	—
FY2023 (FY)	2023-09-30	$29.5M	$4.6M	-$616.9K	-$616.9K	—	—

3. BON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bon Natural Life Limited (Class A) (NASDAQ: BON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.13 (-0.01% 1D, market cap $9.2M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BON ranks #490 in composite RQD confidence.

How does BON compare to NAII and MTEX in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), BON carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 20.8%, and ROIC of —. By comparison, NAII (Natural Alternatives International Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -10.8%, cap $6.9M) and MTEX (Mannatech Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, BON leads on earnings multiple (N/A) while BTMD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BON?

Per BON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001816815), Bon Natural Life Limited (Class A) generated $18.7M in revenue (-21.7% YoY), -$2.0M in net income, and $134.3K in free cash flow against $85.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (21% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BON trading relative to its 50-day, 200-day, and 52-week technical levels?

BON last traded at $1.13 (-0.01% on volume of 1,385 shares), positioning the stock -1.74% below its 50-day simple moving average ($1.15) and -13.08% below its 200-day simple moving average ($1.30). Across its 52-week range of $0.95 to $2.06, BON sits at the 16.2% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($1.02 to $1.24).

BON Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell BON stock right now?

Bon Natural Life Limited (Class A) (BON) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (21% profit margin) under elevated 10-year interest-rate pressure.

What is BON's 12-month price target and RQD AI Jury consensus?

BON's 12-month base price target is $1.06 (range $0.83 to $2.16), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: BON RQD Cockpit BON 12M Forecast BON Earnings & Move BON Dividends & DRIP BON Insiders & 13F BON Whale Options BON Profit Sankey BON News & Why